{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699993865715200.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1056/nejmoa051285"}},{"identifier":{"@type":"URI","@value":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa051285"}},{"identifier":{"@type":"NAID","@value":"30022561454"}}],"dc:title":[{"@value":"A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699993865715074","@type":"Researcher","foaf:name":[{"@value":"Ting-Tsung Chang"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993865715208","@type":"Researcher","foaf:name":[{"@value":"Robert G. Gish"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993865715201","@type":"Researcher","foaf:name":[{"@value":"Robert de Man"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993865715206","@type":"Researcher","foaf:name":[{"@value":"Adrian Gadano"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993865715076","@type":"Researcher","foaf:name":[{"@value":"José Sollano"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993865715207","@type":"Researcher","foaf:name":[{"@value":"You-Chen Chao"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993865715077","@type":"Researcher","foaf:name":[{"@value":"Anna S. Lok"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993865715204","@type":"Researcher","foaf:name":[{"@value":"Kwang-Hyub Han"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993865715203","@type":"Researcher","foaf:name":[{"@value":"Zachary Goodman"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993865715073","@type":"Researcher","foaf:name":[{"@value":"Jin Zhu"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993865715075","@type":"Researcher","foaf:name":[{"@value":"Anne Cross"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993865715072","@type":"Researcher","foaf:name":[{"@value":"Deborah DeHertogh"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993865715202","@type":"Researcher","foaf:name":[{"@value":"Richard Wilber"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993865715205","@type":"Researcher","foaf:name":[{"@value":"Richard Colonno"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993865715200","@type":"Researcher","foaf:name":[{"@value":"David Apelian"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00284793"},{"@type":"EISSN","@value":"15334406"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/00284793"}],"prism:publicationName":[{"@value":"New England Journal of Medicine"}],"dc:publisher":[{"@value":"Massachusetts Medical Society"}],"prism:publicationDate":"2006-03-09","prism:volume":"354","prism:number":"10","prism:startingPage":"1001","prism:endingPage":"1010"},"reviewed":"false","url":[{"@id":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa051285"}],"createdAt":"2006-03-08","modifiedAt":"2019-04-17","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050866901652671616","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Switching to tenofovir disoproxil fumarate vs continuing treatment in chronic hepatitis B patients who maintain long-term virological response to entecavir therapy: a randomized trial"},{"@value":"Switching to tenofovir disoproxil fumarate vs continuing treatment in patients with chronic hepatitis B who maintain long‐term virological response to entecavir therapy: A randomized trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002215326388096","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231260693376","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232280670208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235524768768","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Use of nucleoside analogs in patients with chronic hepatitis B in Nepal: A prospective cohort study in a single hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235757163264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142418892032","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Dual Agonist of Farnesoid X Receptor and Takeda G Protein‐Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142633480320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prophylactic antiviral therapy for hepatitis B virus surface antigen‐positive patients with diffuse large B‐cell lymphoma treated with rituximab‐containing chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013168882600704","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Comparative role of tenofovir versus entecavir for treating patients with hepatitis B virus-related acute on chronic liver failure"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706236945920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285711733152384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714657048832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Sustained Antiviral Effects and Clearance of Hepatitis Surface Antigen after Combination Therapy with Entecavir and Pegylated Interferon in Chronic Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360286995454329216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The antiviral effects of human microRNA miR‐302c‐3p against hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360290617829657088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Screening siRNAs against host glycosylation pathways to develop novel antiviral agents against hepatitis B virus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567180140804864","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of peginterferon alpha‐2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185445755776","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185478217984","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Fatal reactivation of hepatitis B virus infection in a patient with adult T‐cell leukemia–lymphoma receiving the anti‐CC chemokine receptor 4 antibody mogamulizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185710649216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Recommendation of lamivudine‐to‐entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567189430726656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinico-Pathological Importance of TGF-β/Phospho-Smad Signaling during Human Hepatic Fibrocarcinogenesis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256640384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640256676992","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846645722372480","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"TGF-β/Smad signaling during hepatic fibro-carcinogenesis (Review)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656190200320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660687481088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1361694369406341120","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"PD-L1 is induced on the hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 up-regulation by the anti-HBV drug Entecavir"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204790262400","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A non-Hodgkin lymphoma patient with reactivation of HBV during chemotherapy and emergence of a YMDD-motif mutant on lamivudine, eventually controlled by adfovil dipovoxil"},{"@language":"ja","@value":"ＮＨＬに対する化学療法中にＹＭＤＤ変異によりＨＢＶ再活性化をきたし，ａｄｅｆｏｖｉｒ　ｄｉｐｉｖｏｘｉｌ追加投与にて改善した１例"},{"@value":"症例報告 NHLに対する化学療法中にYMDD変異によりHBV再活性化をきたし,adefovir dipivoxil追加投与にて改善した1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク NHL ニ タイスル カガク リョウホウチュウ ニ YMDD ヘンイ ニ ヨリ HBV サイカッセイカ オ キタシ adefovir dipivoxil ツイカ トウヨ ニテ カイゼンシタ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792931840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of liver cirrhosis with refractory ascites treated by peritoneovenous shunt and entecavir"},{"@language":"ja","@value":"難治性腹水を合併した肝硬変に対して腹腔静脈シャント造設後にエンテカビルを投与した１例"},{"@value":"症例報告 難治性腹水を合併した肝硬変に対して腹腔静脈シャント造設後にエンテカビルを投与した1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク ナンジセイ フクスイ オ ガッペイシタ カンコウヘン ニ タイシテ フククウ ジョウミャク シャント ゾウセツゴ ニ エンテカビル オ トウヨシタ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204792984064","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"日本肝臓学会コンセンサス神戸2009：C型肝炎の診断と治療"},{"@language":"en","@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis C"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Cガタ カンエン ノ シンダン ト チリョウ"},{"@value":"日本肝臓学会コンセンサス神戸2009--B型肝炎の診断と治療"},{"@language":"ja-Kana","@value":"ニホン カンゾウ ガッカイ コンセンサス コウベ 2009 Bガタ カンエン ノ シンダン ト チリョウ"},{"@value":"JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204795197696","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of chronic hepatitis B which achieved hepatitis B surface antigen seroclearance during combination therapy with peginterferon alfa-2b and entecavir"},{"@language":"ja","@value":"エンテカビル・ペグインターフェロンα－２ｂ併用４８週治療にてＨＢｓ抗原が消失したＢ型慢性肝炎の１例"},{"@value":"症例報告 エンテカビル・ペグインターフェロンα-2b併用48週治療にてHBs抗原が消失したB型慢性肝炎の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク エンテカビル ・ ペグインターフェロンa-2b ヘイヨウ 48シュウ チリョウ ニテ HBs コウゲン ガ ショウシツ シタ Bガタ マンセイ カンエン ノ 1レイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205035617280","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"リツキシマブ併用化学療法におけるラミブジン予防投与終了後のB型肝炎ウイルス再活性化"},{"@language":"en","@value":"Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy"},{"@value":"症例報告 リツキシマブ併用化学療法におけるラミブジン予防投与終了後のB型肝炎ウイルス再活性化"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク リツキシマブ ヘイヨウ カガク リョウホウ ニ オケル ラミブジン ヨボウ トウヨ シュウリョウゴ ノ Bガタ カンエン ウイルス サイカッセイカ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205746563840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Recent Advances in Hepatitis B Research"},{"@language":"ja","@value":"わが国におけるB型肝炎研究の最近の動向"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679248999040","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"Ｂ型慢性肝炎治療薬エンテカビル水和物（バラクルード錠０．５ｍｇ）の薬理学的特性と臨床効果"},{"@language":"en","@value":"Pharmacological properties and clinical efficacy of entecavir monohydrate (Baraclude<sup>®</sup> Tablet 0.5 mg), an anti-HBV drug"},{"@value":"新薬紹介総説 B型慢性肝炎治療薬エンテカビル水和物(バラクルード錠0.5mg)の薬理学的特性と臨床効果"},{"@language":"ja-Kana","@value":"シンヤク ショウカイ ソウセツ Bガタ マンセイ カンエン チリョウヤク エンテカビル スイワブツ バラクルードジョウ 0 5mg ノ ヤクリガクテキ トクセイ ト リンショウ コウカ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679428284160","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A role of platelets in liver fibrosis"},{"@language":"ja","@value":"肝線維化における血小板の役割"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679769900032","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil"},{"@language":"ja","@value":"アデホビルによる腎障害の検討"},{"@language":"ja-Kana","@value":"アデホビル ニ ヨル ジン ショウガイ ノ ケントウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771909888","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case report of successful therapy with tenofovir for a multi-drug resistant chronic hepatitis B patient complicated with malignant lymphoma"},{"@language":"ja","@value":"多剤耐性変異を認めた悪性リンパ腫合併Ｂ型慢性肝炎に対しテノフォビルが著効した一例"},{"@value":"症例報告 多剤耐性変異を認めた悪性リンパ腫合併B型慢性肝炎に対しテノフォビルが著効した一例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク タザイ タイセイ ヘンイ オ ミトメタ アクセイ リンパ シュ ガッペイ Bガタ マンセイ カンエン ニ タイシ テノフォビル ガ チョコウシタ イチレイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282681377615360","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"B型肝炎の治療-遺伝子型と治療について-"},{"@language":"en","@value":"Therapy for chronic hepatitis B: relationship between HBV genotype and efficacy or resistance of anti-viral therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390852945233580416","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"International cooperation on health and medical care for viral hepatitis: 30 years of activities on comprehensive viral hepatitis control of the JICA group training program for developing countries"}]},{"@id":"https://cir.nii.ac.jp/crid/1570572701031198080","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B : Regression of liver stiffness during entecavir therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1571698600940439808","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"B型・C型肝炎の抗ウイルス療法"},{"@language":"en","@value":"Antiviral therapy for hepatitis B and C infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1571980075378198400","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Drug resistance in antiviral treatment for infections with hepatitis B and C viruses"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105975317212928","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Appropriate use of interferon for treatment of chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1573105975837321088","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effect of nucleoside analog-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1056/nejmoa051285"},{"@type":"CIA","@value":"30022561454"},{"@type":"CROSSREF","@value":"10.1007/s00535-010-0367-5_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1007/s00535-014-1010-7_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1111/hepr.12482_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2010.00739.x_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.42_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1002/hep.31712_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1111/cas.14846_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.4103/jfmpc.jfmpc_2299_20_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0742-5_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1182/asheducation-2014.1.576_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1111/apt.15197_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1016/j.jhep.2009.12.036_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.2957/kanzo.48.309_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.2957/kanzo.51.243_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.2957/kanzo.49.426_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.2957/kanzo.53.35_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.2491/jjsth.22.71_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.35772/ghm.2021.01068_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1111/hepr.13552_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1002/jmv.23564_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1111/cei.12259_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1111/hepr.12513_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2011.00807.x_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.3390/cancers10060183_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.2957/kanzo.52.102_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.3851/imp3225_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0737-2_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1007/s00535-013-0864-4_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1007/s00535-012-0645-5_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1111/j.1872-034x.2011.00910.x_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.3892/ijo.2014.2552_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1254/fpj.129.287_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.14789/pjmj.55.443_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1002/jmv.25442_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"},{"@type":"CROSSREF","@value":"10.1093/intimm/dxaa018_references_DOI_K8bed5ij0IpfIYdmYN0KK3MvjlB"}]}